A Double-blind Randomized Placebo Controlled Dose-finding Trial to Investigate Different Doses of a New Antiviral Drug in Subjects With Genital HSV Type 2 Infection.

Trial Profile

A Double-blind Randomized Placebo Controlled Dose-finding Trial to Investigate Different Doses of a New Antiviral Drug in Subjects With Genital HSV Type 2 Infection.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs Pritelivir (Primary)
  • Indications Herpes genitalis; Herpes simplex virus type 2 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Jan 2014 Results published in the New England Journal of Medicine.
    • 16 Apr 2012 Results will be presented at the 2012 International Conference on Antiviral Research according to an AiCuris media release. Results will be presented at other international meetings also.
    • 05 Sep 2011 Results of a 'resistance analysis' will be presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), according to an AiCuris media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top